UrbanZone/E+ via Getty Images
Introduction
Moonlake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biotech firm, uses nanobody technology to create advanced drugs for immunological diseases, with an emphasis on their tri-specific nanobody, sonelokimab, for inflammatory conditions such as hidradenitis suppurativa . [HS],
I previously evaluated MoonLeck, especially given their promising status with the innovative nanobody therapy, sonelokimab, following encouraging phase 2 MIRA trial results for HS treatment. However, I cautioned investors about a premature valuation increase, and stressed the need for sonelocimab to outperform Humira in future trials. Additional concerns arose from the company’s financial condition and potential shareholder dilution. I labeled their stock as potentially speculative and advised a “Hold” position, emphasizing the importance of upcoming clinical results. Personally, I chose a cautious approach while waiting for clear results.
The following article discusses Moonlake’s financial growth, promising drug development, and my revised recommendation to “buy” their stock.
Q2 Earnings Report
Looking at Moonlake’s most recent earnings report, the company successfully raised $460 million from the sale of 8,000,000 Class A ordinary shares and an additional 1,200,000 shares due to the underwriters exercising their full options. In addition, he made $15.2 million by selling 544,894 shares through an at-the-market facility. As of June 30, 2023, Moonlake had cash reserves of $501.8M, a substantial increase from $63.1M at the end of March 2023. Research and development spending increased by $1.3M to reach $8.7M, primarily due to the MIRA and ARGO studies. Conversely, general and administrative costs decreased from $5.5M to $4.5M, which was attributed to a decrease in professional services and share-based compensation expenses.
Cash Runway and Liquidity
Turning to Moonlake’s balance sheet, the combined value under ‘assets’ for ‘cash and cash equivalents’ is $501.8M. Over the last six months, the company has used $21.2 million of net cash flow from operating activities. This means a monthly cash outlay of approximately $3.5M. Given this burn rate, the company has a cash runway of approximately 143 months based on its combined assets. However, it is essential to remember that these values and projections are based on past data and may not reflect future performance. In addition, Moonlake is gearing up for an extensive Phase 3 clinical program.[s]Investors should be prepared for increased R&D costs.
Moonlake’s liquidity appears strong, with significant cash assets and a relatively long runway. Current liabilities are $7.1 million, which is easily covered by their liquid assets. In addition, there is no apparent debt beyond operating lease liabilities and pension liabilities. Given the firm’s current financial position, it seems plausible that they can secure additional financing if necessary. These observations and/or estimates are my own and may differ from other analyses.
assessment, growth and momentum
According to Seeking Alpha data: Moonlake exhibits a strong capital structure with a significant cash position relative to its market capitalization and minimal debt. The enterprise value is $2.48B. Moonlake has received positive sentiment on the development, despite being in the pre-revenue stage, indicating high future earnings potential, although it is imperative to acknowledge the inherent uncertainties in drug development. The stock has shown strong momentum, outperforming the S&P 500 at various intervals.
Data by YCharts
Moonlake leads the way in innovation
In Q2 2023, Moonlake has significantly expanded its research horizons based on key strategic partnerships and data-driven insights. This expansion holds implications not only for the direction of the company, but also for the stakeholders and potential beneficiaries of their medical advances.
Capital Markets Day on April 19th presented an opportunity for leadership to articulate the Company’s vision and goals, particularly with respect to the dynamic HS treatment landscape. This active engagement reflects Moonlake’s strategic commitment to staying ahead of changes in the industry.
The collaboration launched on May 3 with SHL Medical represents the blending of Moonlake’s research prowess with device innovation. The development of an autoinjector for sonelocimab potentially simplifies the treatment process, hinting at the company’s penchant for end-user convenience and product differentiation.
The results released on June 25 from the Phase 2 MIRA trial represent a remarkable milestone in Moonlake’s research trajectory. Sonelocimab exhibits a remarkable clinical activity by week 12 compared to placebo, indicating a potential dominance of the treatment in the HS domain. In addition, a top-line 24-week data readout from this trial is eagerly expected by mid-October 2023.
Furthering their research efforts, the July 25 announcement of the completion of patient randomization for the Phase 2 ARGO trial in PSA ahead of schedule underscores the company’s operational efficiency. With the top-line 12-week data for the PSA test to be released in November, stakeholders can expect more comprehensive insights into the efficacy and scope of treatment.
The upcoming Capital Markets Day on September 11, 2023, promises an in-depth exploration into the PSA market, along with updates on Moonlake’s other research areas. This association underlines the company’s continuous approach to keep its stakeholders informed about its progress and research results.
In reviewing Moonlake’s activities and announcements through the second quarter of 2023, it is clear that the company is taking measured steps to advance the treatment of HS and PsA. For investors and industry observers, these developments provide an informative lens through which to assess the company’s direction and potential impact in the medical field.
my analysis and recommendation
Moonlake has undoubtedly traveled a transformational journey since our last evaluation, demonstrating both financial resilience and an unwavering commitment to innovative treatments. The company’s enhanced cash reserves not only allays prior concerns about its financial position, but also enables Moonlake to capitalize on upcoming opportunities. Their liquidity, when compared with their lack of solid debt, paints a picture of a company that’s on solid footing even in a volatile biotech sector.
Moonlake’s strategic foresight is equally commendable. By fostering synergistic partnerships like SHL Medical’s, and through diligent pursuit of clinical trials, they are setting the stage for potential game-changers in the treatment of HS and PsA. The results of the Phase 2 MIRA trial of sonelocimab specifically point to a therapeutic breakthrough, which promises an improved patient experience. It is important for investors to closely monitor the 24-week data readouts from this test in October and the PSA test results in November, as these will be instrumental in further understanding Moonlake’s potential in the market.
Given the company’s improved financial position, the undeniable promise of sonelokimab, and the orderly execution of its strategic efforts, I am revising my earlier stance. I now recommend an upgrade to “Buy” status for Moonlake. Investors will be investing not only in a firm with a solid balance sheet, but also in a company that is at the forefront of potentially revolutionary treatments in the field of immunological diseases. Like all investments, especially in the biotech sector, one should approach them with an understanding of the risks, but in Moonlake’s case, the future appears promising.
exposure to thesis
I change my mind when facts change.
Although my assessment of Moonlake Immunotherapeutics is optimistic, there are some risks worth acknowledging:
- Clinical Trial Uncertainties: Although the Phase 2 MIRA trial showed promising results, it is important to remember that later trials may not produce the same favorable results. Clinical progress cannot be predicted with certainty, and there is always the potential for unexpected adverse reactions or reduced effectiveness. If “breakthrough” is achieved, Moonlake’s sonelocimab will still face comparisons with Humira. Any perception of its inferiority could have a negative impact on Moonlake’s stock price.
- competitive landscape: The biotech industry is dynamic, with competitors constantly vying for dominance. A competing product may gain popularity, outperform sonelocimab, or make it obsolete.
- Regulatory Constraints: Despite successful trials, regulatory approval is not certain. The FDA or other international bodies may delay or deny approval.
- Commercialization Challenges: A successful drug in trials does not guarantee success in the market. There may be challenges in production, distribution, or adoption by physicians and patients.
- More emphasis on cash reserves: Although the current financial position looks strong, rapidly rising or unexpected expenses can quickly deplete the reserves.
- market sentiment: Biotech stocks are extremely volatile. Regardless of the company’s performance, external factors or a broader market downturn could adversely affect Moonlake’s stock price. Furthermore, since MLTX is up over 600% YTD, it would not be surprising to see significant volatility to the downside in the short term without any news.
- prejudice: I may have unconscious biases due to the company’s recent successes, which has caused my outlook to be overly optimistic.
Source: seekingalpha.com
